KDR and pulmonary fibrosis: In order to prevent a further worsening of the pulmonary fibrosis, the young girl was enrolled in a clinical trial with Nintedanib, a tyrosine kinase inhibitor targeting endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) [12].